| Prev Close | 4.30 |
| Open | 4.29 |
| Day Low/High | 4.15 / 4.30 |
| 52 Wk Low/High | 2.02 / 13.49 |
| Volume | 103.67K |
| Avg Volume | 214.40K |
DBV Technologies SA (DBVT)
4.20
0.10
2.33
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 109.85M |
| Market Cap | 504.89M |
| EPS | -2.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
My Stock of the Week Is Aimmune Therapeutics
AIMT has developed a 'desensitivity' treatment for peanut allergies.
This Under-the-Radar Biotech Stock Is My Top Pick for 2019
The stock's decline with the sector has occurred despite a steady supply of positive news.
Versartis Pops, DBV Wild Ride Continues -- Biotech Movers
Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.
DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
These Stocks Are Trending Up With Monster Volume
Let's take a look at several stocks that are experiencing unusual volume activity.